RARE - Ultragenyx Pharmaceutical Q4 2022 Earnings Preview
- Ultragenyx Pharmaceutical ( NASDAQ: RARE ) is scheduled to announce Q4 earnings results on Thursday, February 16th, after market close.
- The consensus EPS Estimate is -$1.80 and the consensus Revenue Estimate is $105.11M (+26.0% Y/Y).
- Over the last 3 months, EPS estimates have seen 2 upward revisions and 0 downward. Revenue estimates have seen 5 upward revisions and 1 downward.
For further details see:
Ultragenyx Pharmaceutical Q4 2022 Earnings Preview